# A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

> **NCT02753218** · PHASE1 · TERMINATED · sponsor: **LEO Pharma** · enrollment: 12 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** Midazolam
- **DRUG:** LEO 32731

## Key facts

- **NCT ID:** NCT02753218
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Due to tolerability issues related to the dose titration, unexpected withdrawals were observed and it was unlikely for the trial to meet its objectives
- **Last updated:** 2017-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02753218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02753218, "A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02753218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*